SCHEMBL683590

SCHEMBL683590

Cn1c(=O)c2c(ncn2CC(O)CN2CCCN(Cc3ccc(Cl)c(Cl)c3)CC2)n(C)c1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.64
LMNA P02545 5/20 0.64
HTT P42858 2/20 0.64
UBE2N P61088 2/20 0.64
POLB P06746 2/20 0.53
MAOB P27338 4/20 0.52
ADORA2A P29274 1/20 0.52
ADORA1 P30542 1/20 0.52
RXFP1 Q9HBX9 4/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GLA P06280 1/20 0.48
GAA P10253 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ABCC8 Q09428 1/20 0.46
KCNJ11 Q14654 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684337 0.97 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHTTUBE2NPOLB
SCHEMBL682806 0.91 LMNA (0.62) SMN1; SMN2LMNAHTTUBE2NPOLB
SCHEMBL683975 0.88 LMNA (0.65) SMN1; SMN2LMNAHTTUBE2NPOLB
SCHEMBL684003 0.86 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHTTUBE2NPOLB
SCHEMBL684348 0.85 SMN1; SMN2 (0.69) SMN1; SMN2LMNAHTTUBE2NMAOB
SCHEMBL682800 0.85 RXFP1 (0.63) SMN1; SMN2LMNAPOLBRXFP1L3MBTL1
SCHEMBL684353 0.85 SMN1; SMN2 (0.54) SMN1; SMN2LMNAHTTUBE2NPOLB
SCHEMBL684000 0.85 SMN1; SMN2 (0.65) SMN1; SMN2LMNAHTTUBE2NPOLB
SCHEMBL683589 0.85 ALDH1A1 (0.54) SMN1; SMN2LMNAPOLBMAOBADORA2A
Hydrochloric Acid SCHEMBL10896818 0.85 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHTTUBE2NMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF SMN1; SMN2 907/4885LMNA 2155/4885HTT 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.